| Name : R-drugdevelopR
| |
| Version : 1.0.1
| Vendor : obs://build_opensuse_org/devel:languages:R
|
| Release : lp155.2.1
| Date : 2024-09-10 05:12:18
|
| Group : Development/Libraries/Other
| Source RPM : R-drugdevelopR-1.0.1-lp155.2.1.src.rpm
|
| Size : 1.52 MB
| |
| Packager : https://www_suse_com/
| |
| Summary : Utility-Based Optimal Phase II/III Drug Development Planning
|
Description :
Plan optimal sample size allocation and go/no-go decision rules for
phase II/III drug development programs with time-to-event, binary or
normally distributed endpoints when assuming fixed treatment effects or
a prior distribution for the treatment effect, using methods from
Kirchner et al. (2016) < doi:10.1002/sim.6624> and Preussler (2020).
Optimal is in the sense of maximal expected utility, where the utility
is a function taking into account the expected cost and benefit of the
program. It is possible to extend to more complex settings with bias
correction (Preussler S et al. (2020)
< doi:10.1186/s12874-020-01093-w>), multiple phase III trials (Preussler
et al. (2019) < doi:10.1002/bimj.201700241>), multi-arm trials
(Preussler et al. (2019) < doi:10.1080/19466315.2019.1702092>), and
multiple endpoints (Kieser et al. (2018) < doi:10.1002/pst.1861>).
|
RPM found in directory: /packages/linux-pbone/ftp5.gwdg.de/pub/opensuse/repositories/devel:/languages:/R:/autoCRAN/15.5/x86_64 |
